Growth and capex

The pharmaceuticals industry is capital intensive. The industry requires large investments in order to have manufacturing and research and development, or R&D, facilities. Johnson & Johnson (JNJ) is working on various organic and inorganic growth strategies in order to maintain its position as a leading pharmaceutical company worldwide.

 Understanding Johnson & Johnson’s Growth Strategies

Johnson & Johnson’s net spending in the purchase of property, plant, and machinery in 2013 was over $3 billion. It was more than 100% of the net spending in 2012. This indicates that the company is spending on capital assets.

Acquisitions for growth

The figures represented in the above chart are net of cash acquired. Under the inorganic growth strategy, the company constantly acquires smaller companies. In 2013, certain businesses were acquired for $835 million in cash and $193 million of assumed liabilities. The 2013 acquisitions included Aragon Pharmaceuticals, Shanghani Elsker For Mother & Baby Co. Ltd., and Flexible Stenting Solutions, Inc.

In 2012, certain businesses were acquired for $17.8 billion in cash and stock and nearly $1.2 billion of assumed liabilities. The 2012 acquisitions include Synthes, Guangzhou Bioseal Biotech Co. Ltd., Angiotech Pharmaceuticals, Corimmun GmbH, Calibra Medical, and Spectrum Vision LLC.

The above graph shows the company’s focus on organic and inorganic growth. The company’s spending on capital assets indicates its willingness for organic growth. The spending on the acquisitions indicates its willingness for inorganic growth. Recently, the company acquired many companies in order to strengthen its presence in all three of its segments—Pharmaceuticals, Consumer Products, and Medical Devices and Diagnostics.

Johnson & Johnson also opted to divest its businesses. In 2013, the company opted to divest women’s sanitary protection products in the US, Canada, and the Caribbean markets. In 2014, the company opted to divest its Ortho-Clinical Diagnostics business.

Other deals

In 2013, Amgen (AMGN) acquired Onyx Pharmaceuticals. Cubist Pharmaceuticals (CBST) acquired Trius Therapeutics. Also, AbbVie (ABBV) called off its proposed $55 billion acquisition of Shire Plc (SHP). AbbVie forms 3.61% of the total assets of the Health Care Select Sector SPDR ETF (XLV).

Latest articles

23 Jul

Will Fortinet Beat Q2 Earnings Estimates?

WRITTEN BY Aditya Raghunath

Leading cybersecurity company Fortinet (FTNT) is scheduled to announce its second-quarter earnings results on August 1. What should we expect?

Harley-Davidson’s Q2 earnings were slightly better than estimates.

Netflix (NFLX) has long relied on international markets to drive its streaming video business growth.

23 Jul

Could Ford’s Q2 Earnings Push Its Stock Even Higher?

WRITTEN BY Mohit Oberoi, CFA

Ford's second-quarter earnings results are scheduled for release on July 24. So far, Ford stock has outperformed its legacy peers.

23 Jul

Why RBC Isn't Optimistic about BlackBerry Stock

WRITTEN BY Aditya Raghunath

Shares of BlackBerry (BB) have been volatile over the last 12 months. BlackBerry stock fell 40.5% from $12.0 in September 2018 to $6.57 in December.

According to a Wall Street Journal report, Apple (AAPL) could be interested in buying Intel’s modem chip business.